Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...
Targeted Oncology3d
Lasofoxifene Shows Promise in Lowering Ki-67 Levels in HR+/HER2- Breast Cancer
Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with ...
The American Journal of Managed Care3d
Breast Cancer Challenges and Promises in Immunotherapy
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third ...
Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts
Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...
The Globe and Mail5d
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in HR+ HER2-ve Breast ...
T-Net1d
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...
Predicinecare™ Liquid Biopsy Assay Featured In NEJM As Pivotal Tool In Roche’S Phase III Itovebi Breast Cancer Trial
PredicineCARETM was utilized to identify and enroll patients with PIK3CA-mutated metastatic breast cancer in China, a key component contributing to t ...
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...
Exact Sciences Has an Established Colon Cancer Screening Franchise and a Progressing Pipeline
Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...